Payment overview · 2025
General Payments
$809.32
37 reported records · 18 companies
Healthcare provider profile · identity verified
Jared Duane Gunnell, PA-C
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant · MESA, AZ · NPI 1366791873
Verified facts
What the public records show
CMS Open Payments records show Jared Duane Gunnell, PA-C received $809.32 in general payments during 2025 across 37 reported records.
Lilly USA, LLC accounted for 18.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 25 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $148.75 | 18.4% | 9 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $134.96 | 16.7% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $70.70 | 8.7% | 4 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $57.88 | 7.2% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $57.19 | 7.1% | 3 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $56.28 | 7.0% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $44.30 | 5.5% | 2 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $36.67 | 4.5% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $34.43 | 4.2% | 1 | 2025 |
| Averitas Pharma Inc. | Unresolved — no canonical attribution shown | $26.18 | 3.2% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $23.34 | 2.9% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $21.87 | 2.7% | 1 | 2025 |
| COLOPLAST CORP | Unresolved — no canonical attribution shown | $18.13 | 2.2% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $17.65 | 2.2% | 1 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.06 | 2.0% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $15.69 | 1.9% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $15.43 | 1.9% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $13.81 | 1.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $809.32 | 37 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $134.96 | 3 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $57.88 | 2 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $57.19 | 3 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $56.28 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $55.80 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $52.68 | 3 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $44.30 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $44.30 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $44.30 | 2 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $40.27 | 3 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $36.67 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $36.04 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $34.43 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $34.43 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $30.09 | 2 | 2025 |
Source payment records
|
|||||
| QUTENZA Normalized: qutenza |
Drug | Averitas Pharma Inc. | $26.18 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $23.34 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $21.87 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $21.20 | 1 | 2025 |
Source payment records
|
|||||
| Titan Normalized: titan |
Device | COLOPLAST CORP | $18.13 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $17.65 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $15.69 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $15.69 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $15.43 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $13.81 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 46 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
46 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
66 | 21 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
16 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 263 | 80 |
| Atorvastatin Calcium | Atorvastatin Calcium | 245 | 86 |
| Lisinopril | Lisinopril | 228 | 79 |
| Amlodipine Besylate | Amlodipine Besylate | 216 | 75 |
| Tamsulosin Hcl | Tamsulosin Hcl | 172 | 63 |
| Losartan Potassium | Losartan Potassium | 152 | 57 |
| Diclofenac Sodium | Diclofenac Sodium | 141 | 49 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 129 | 45 |
| Hydrochlorothiazide | Hydrochlorothiazide | 125 | 39 |
| Azithromycin | Azithromycin | 122 | 115 |
| Prednisone | Prednisone | 118 | 109 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 117 | 51 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 116 | 102 |
| Pantoprazole Sodium | Pantoprazole Sodium | 113 | 45 |
| Gabapentin | Gabapentin | 112 | 48 |
| Metformin Hcl | Metformin Hcl | 108 | 40 |
| Omeprazole | Omeprazole | 105 | 42 |
| Sertraline Hcl | Sertraline Hcl | 101 | 31 |
| Metoprolol Succinate | Metoprolol Succinate | 100 | 36 |
| Tramadol Hcl | Tramadol Hcl | 100 | 48 |
| Zolpidem Tartrate | Zolpidem Tartrate | 83 | 27 |
| Alprazolam | Alprazolam | 74 | 23 |
| Metoprolol Tartrate | Metoprolol Tartrate | 74 | 20 |
| Simvastatin | Simvastatin | 71 | 24 |
| Eliquis | Apixaban | 66 | 21 |
| Allopurinol | Allopurinol | 65 | 19 |
| Pravastatin Sodium | Pravastatin Sodium | 65 | 22 |
| Meloxicam | Meloxicam | 63 | 20 |
| Temazepam | Temazepam | 60 | 11 |
| Lorazepam | Lorazepam | 58 | 20 |
| Finasteride | Finasteride | 56 | 20 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 53 | 29 |
| Furosemide | Furosemide | 52 | 28 |
| Pregabalin | Pregabalin | 52 | 21 |
| Tizanidine Hcl | Tizanidine Hcl | 52 | 30 |
| Clopidogrel | Clopidogrel Bisulfate | 50 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 49 | 18 |
| Jardiance | Empagliflozin | 46 | 20 |
| Montelukast Sodium | Montelukast Sodium | 46 | 16 |
| Atenolol | Atenolol | 43 | 14 |
| Carvedilol | Carvedilol | 43 | 18 |
| Trazodone Hcl | Trazodone Hcl | 42 | 21 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 41 | 39 |
| Potassium Chloride | Potassium Chloride | 39 | 16 |
| Methylprednisolone | Methylprednisolone | 38 | 38 |
| Xarelto | Rivaroxaban | 38 | 16 |
| Ezetimibe | Ezetimibe | 32 | 12 |
| Linzess | Linaclotide | 29 | suppressed |
| Clonazepam | Clonazepam | 28 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 28 | suppressed |
| Celecoxib | Celecoxib | 27 | 11 |
| Ibuprofen | Ibuprofen | 27 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 26 | suppressed |
| Ozempic | Semaglutide | 25 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 24 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 24 | 13 |
| Valsartan | Valsartan | 24 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 23 | suppressed |
| Lovastatin | Lovastatin | 23 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 23 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Fenofibrate | Fenofibrate | 22 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | 11 |
| Mounjaro | Tirzepatide | 22 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 21 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 21 | 11 |
| Irbesartan | Irbesartan | 21 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 21 | suppressed |
| Baclofen | Baclofen | 20 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 20 | suppressed |
| Cephalexin | Cephalexin | 20 | 16 |
| Diazepam | Diazepam | 20 | suppressed |
| Nifedipine Er | Nifedipine | 20 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 19 | suppressed |
| Glipizide Er | Glipizide | 19 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 19 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 19 | suppressed |
| Acyclovir | Acyclovir | 18 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 18 | suppressed |
| Nystatin | Nystatin | 17 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 16 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 16 | 16 |
| Ropinirole Hcl | Ropinirole Hcl | 16 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 16 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 16 | 12 |
| Fluconazole | Fluconazole | 15 | 11 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 15 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 14 | suppressed |
| Famotidine | Famotidine | 14 | suppressed |
| Mirtazapine | Mirtazapine | 14 | suppressed |
| Amoxicillin | Amoxicillin | 13 | 12 |
| Bupropion Xl | Bupropion Hcl | 13 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 13 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 13 | suppressed |
| Lansoprazole | Lansoprazole | 13 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 12 | 12 |
| Digoxin | Digoxin | 12 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 12 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 12 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 12 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 12 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 11 | suppressed |
| Ec-Naproxen | Naproxen | 11 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $809.32 · 37 records | Lilly USA, LLC | ABRYSVO, AIRSUPRA, CAPVAXIVE, COMIRNATY, Dexcom G6 Transmitter, FREESTYLE LIBRE 3, GARDASIL 9, INSPIRE, JARDIANCE, KISUNLA, MOUNJARO, Ozempic, PREVNAR 20, QULIPTA, QUTENZA, REXULTI, Sunosi, TRELEGY ELLIPTA, Titan, UBRELVY, Veozah, WATCHMAN FLX, Wegovy, YUPELRI, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error